Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan ("Bened"). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LP_LDL®, in Taiwan, with the aim of maximising the financial return for both parties.

OptiBiotix previously announced (RNS: 13 September 2017) the signing of a Memorandum of Understanding with Bened to explore licensing and sales opportunities. This announcement confirms the successful conclusion of those discussions. Bened Biomedical Co., Ltd., was founded in 2015 as a spin off from National Yang-Ming University ("NYMU") by Professor Tsai, Ying-Chieh. Bened is a leading probiotic research and marketing companies in Asia developing microbiome based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders.

This agreement expands OptiBiotix's sale into Taiwan with the potential to broaden the opportunity within the Asia Pacific region. Cardiovascular disease is the second leading cause of death in Taiwan, behind Cancer, and is seen as a major public health issue. The Taiwanese supplements market is predicted to grow by a 27% growth by 2021. The agreement creates a pathway to access territories in the Asia Pacific region with a total probiotic retail value of $16.1 billion, of which supplements are $700 million.

Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).

Per Rehne, Commercial Director of OptiBiotix, said: "We are pleased to announce this licence agreement with Bened Biomedical which opens up the commercial opportunity for LP_LDL® in Taiwan and the wider Asia Pacific Region. Bened have expressed confidence in developing and commercialising food supplement containing LP_LDL® and we see it as an important step to extend global reach of LP_LDL®. This is the 13th agreement for LP_LDL® over the last 18 months.

"This is a strategic step in developing the sales channels into the Asian probiotic markets and the commercial reach of OptiBiotix's LP_LDL® strain. Enhancing our presence in Asia allows OptiBiotix to offer multiple product solutions through partnerships with consumer health and pharmaceutical companies, which has the potential to create multiple revenue streams, including those coming from the newly launched CholBiome products containing LP_LDL®."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan ("Bened"). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LP_LDL®, in Taiwan, with the aim of maximising the financial return for both parties.

OptiBiotix previously announced (RNS: 13 September 2017) the signing of a Memorandum of Understanding with Bened to explore licensing and sales opportunities. This announcement confirms the successful conclusion of those discussions. Bened Biomedical Co., Ltd., was founded in 2015 as a spin off from National Yang-Ming University ("NYMU") by Professor Tsai, Ying-Chieh. Bened is a leading probiotic research and marketing companies in Asia developing microbiome based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders.

This agreement expands OptiBiotix's sale into Taiwan with the potential to broaden the opportunity within the Asia Pacific region. Cardiovascular disease is the second leading cause of death in Taiwan, behind Cancer, and is seen as a major public health issue. The Taiwanese supplements market is predicted to grow by a 27% growth by 2021. The agreement creates a pathway to access territories in the Asia Pacific region with a total probiotic retail value of $16.1 billion, of which supplements are $700 million.

Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).

Per Rehne, Commercial Director of OptiBiotix, said: "We are pleased to announce this licence agreement with Bened Biomedical which opens up the commercial opportunity for LP_LDL® in Taiwan and the wider Asia Pacific Region. Bened have expressed confidence in developing and commercialising food supplement containing LP_LDL® and we see it as an important step to extend global reach of LP_LDL®. This is the 13th agreement for LP_LDL® over the last 18 months.

"This is a strategic step in developing the sales channels into the Asian probiotic markets and the commercial reach of OptiBiotix's LP_LDL® strain. Enhancing our presence in Asia allows OptiBiotix to offer multiple product solutions through partnerships with consumer health and pharmaceutical companies, which has the potential to create multiple revenue streams, including those coming from the newly launched CholBiome products containing LP_LDL®."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan ("Bened"). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LP_LDL®, in Taiwan, with the aim of maximising the financial return for both parties.

OptiBiotix previously announced (RNS: 13 September 2017) the signing of a Memorandum of Understanding with Bened to explore licensing and sales opportunities. This announcement confirms the successful conclusion of those discussions. Bened Biomedical Co., Ltd., was founded in 2015 as a spin off from National Yang-Ming University ("NYMU") by Professor Tsai, Ying-Chieh. Bened is a leading probiotic research and marketing companies in Asia developing microbiome based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders.

This agreement expands OptiBiotix's sale into Taiwan with the potential to broaden the opportunity within the Asia Pacific region. Cardiovascular disease is the second leading cause of death in Taiwan, behind Cancer, and is seen as a major public health issue. The Taiwanese supplements market is predicted to grow by a 27% growth by 2021. The agreement creates a pathway to access territories in the Asia Pacific region with a total probiotic retail value of $16.1 billion, of which supplements are $700 million.

Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).

Per Rehne, Commercial Director of OptiBiotix, said: "We are pleased to announce this licence agreement with Bened Biomedical which opens up the commercial opportunity for LP_LDL® in Taiwan and the wider Asia Pacific Region. Bened have expressed confidence in developing and commercialising food supplement containing LP_LDL® and we see it as an important step to extend global reach of LP_LDL®. This is the 13th agreement for LP_LDL® over the last 18 months.

"This is a strategic step in developing the sales channels into the Asian probiotic markets and the commercial reach of OptiBiotix's LP_LDL® strain. Enhancing our presence in Asia allows OptiBiotix to offer multiple product solutions through partnerships with consumer health and pharmaceutical companies, which has the potential to create multiple revenue streams, including those coming from the newly launched CholBiome products containing LP_LDL®."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan ("Bened"). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LP_LDL®, in Taiwan, with the aim of maximising the financial return for both parties.

OptiBiotix previously announced (RNS: 13 September 2017) the signing of a Memorandum of Understanding with Bened to explore licensing and sales opportunities. This announcement confirms the successful conclusion of those discussions. Bened Biomedical Co., Ltd., was founded in 2015 as a spin off from National Yang-Ming University ("NYMU") by Professor Tsai, Ying-Chieh. Bened is a leading probiotic research and marketing companies in Asia developing microbiome based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders.

This agreement expands OptiBiotix's sale into Taiwan with the potential to broaden the opportunity within the Asia Pacific region. Cardiovascular disease is the second leading cause of death in Taiwan, behind Cancer, and is seen as a major public health issue. The Taiwanese supplements market is predicted to grow by a 27% growth by 2021. The agreement creates a pathway to access territories in the Asia Pacific region with a total probiotic retail value of $16.1 billion, of which supplements are $700 million.

Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).

Per Rehne, Commercial Director of OptiBiotix, said: "We are pleased to announce this licence agreement with Bened Biomedical which opens up the commercial opportunity for LP_LDL® in Taiwan and the wider Asia Pacific Region. Bened have expressed confidence in developing and commercialising food supplement containing LP_LDL® and we see it as an important step to extend global reach of LP_LDL®. This is the 13th agreement for LP_LDL® over the last 18 months.

"This is a strategic step in developing the sales channels into the Asian probiotic markets and the commercial reach of OptiBiotix's LP_LDL® strain. Enhancing our presence in Asia allows OptiBiotix to offer multiple product solutions through partnerships with consumer health and pharmaceutical companies, which has the potential to create multiple revenue streams, including those coming from the newly launched CholBiome products containing LP_LDL®."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan ("Bened"). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LP_LDL®, in Taiwan, with the aim of maximising the financial return for both parties.

OptiBiotix previously announced (RNS: 13 September 2017) the signing of a Memorandum of Understanding with Bened to explore licensing and sales opportunities. This announcement confirms the successful conclusion of those discussions. Bened Biomedical Co., Ltd., was founded in 2015 as a spin off from National Yang-Ming University ("NYMU") by Professor Tsai, Ying-Chieh. Bened is a leading probiotic research and marketing companies in Asia developing microbiome based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders.

This agreement expands OptiBiotix's sale into Taiwan with the potential to broaden the opportunity within the Asia Pacific region. Cardiovascular disease is the second leading cause of death in Taiwan, behind Cancer, and is seen as a major public health issue. The Taiwanese supplements market is predicted to grow by a 27% growth by 2021. The agreement creates a pathway to access territories in the Asia Pacific region with a total probiotic retail value of $16.1 billion, of which supplements are $700 million.

Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).

Per Rehne, Commercial Director of OptiBiotix, said: "We are pleased to announce this licence agreement with Bened Biomedical which opens up the commercial opportunity for LP_LDL® in Taiwan and the wider Asia Pacific Region. Bened have expressed confidence in developing and commercialising food supplement containing LP_LDL® and we see it as an important step to extend global reach of LP_LDL®. This is the 13th agreement for LP_LDL® over the last 18 months.

"This is a strategic step in developing the sales channels into the Asian probiotic markets and the commercial reach of OptiBiotix's LP_LDL® strain. Enhancing our presence in Asia allows OptiBiotix to offer multiple product solutions through partnerships with consumer health and pharmaceutical companies, which has the potential to create multiple revenue streams, including those coming from the newly launched CholBiome products containing LP_LDL®."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan ("Bened"). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LP_LDL®, in Taiwan, with the aim of maximising the financial return for both parties.

OptiBiotix previously announced (RNS: 13 September 2017) the signing of a Memorandum of Understanding with Bened to explore licensing and sales opportunities. This announcement confirms the successful conclusion of those discussions. Bened Biomedical Co., Ltd., was founded in 2015 as a spin off from National Yang-Ming University ("NYMU") by Professor Tsai, Ying-Chieh. Bened is a leading probiotic research and marketing companies in Asia developing microbiome based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders.

This agreement expands OptiBiotix's sale into Taiwan with the potential to broaden the opportunity within the Asia Pacific region. Cardiovascular disease is the second leading cause of death in Taiwan, behind Cancer, and is seen as a major public health issue. The Taiwanese supplements market is predicted to grow by a 27% growth by 2021. The agreement creates a pathway to access territories in the Asia Pacific region with a total probiotic retail value of $16.1 billion, of which supplements are $700 million.

Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).

Per Rehne, Commercial Director of OptiBiotix, said: "We are pleased to announce this licence agreement with Bened Biomedical which opens up the commercial opportunity for LP_LDL® in Taiwan and the wider Asia Pacific Region. Bened have expressed confidence in developing and commercialising food supplement containing LP_LDL® and we see it as an important step to extend global reach of LP_LDL®. This is the 13th agreement for LP_LDL® over the last 18 months.

"This is a strategic step in developing the sales channels into the Asian probiotic markets and the commercial reach of OptiBiotix's LP_LDL® strain. Enhancing our presence in Asia allows OptiBiotix to offer multiple product solutions through partnerships with consumer health and pharmaceutical companies, which has the potential to create multiple revenue streams, including those coming from the newly launched CholBiome products containing LP_LDL®."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.